نتایج جستجو برای: amphotericin

تعداد نتایج: 7081  

2016
Armando Antillón Alexander H. de Vries Marcel Espinosa-Caballero José Marcos Falcón-González David Flores Romero Javier González–Damián Fabiola Eloísa Jiménez-Montejo Angel León-Buitimea Manuel López-Ortiz Ricardo Magaña Siewert J. Marrink Rosmarbel Morales-Nava Xavier Periole Jorge Reyes-Esparza Josué Rodríguez Lozada Tania Minerva Santiago-Angelino María Cristina Vargas González Ignacio Regla Mauricio Carrillo-Tripp Mario Fernández-Zertuche Lourdes Rodríguez-Fragoso Iván Ortega-Blake

Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage. The molecular mechanism of polyene has also been closely studied for this purpose and understanding it would contribute to the development of safe derivati...

Journal: :The New England journal of medicine 2018
Síle F Molloy Cecilia Kanyama Robert S Heyderman Angela Loyse Charles Kouanfack Duncan Chanda Sayoki Mfinanga Elvis Temfack Shabir Lakhi Sokoine Lesikari Adrienne K Chan Neil Stone Newton Kalata Natasha Karunaharan Kate Gaskell Mary Peirse Jayne Ellis Chimwemwe Chawinga Sandrine Lontsi Jean-Gilbert Ndong Philip Bright Duncan Lupiya Tao Chen John Bradley Jack Adams Charles van der Horst Joep J van Oosterhout Victor Sini Yacouba N Mapoure Peter Mwaba Tihana Bicanic David G Lalloo Duolao Wang Mina C Hosseinipour Olivier Lortholary Shabbar Jaffar Thomas S Harrison

BACKGROUND Cryptococcal meningitis accounts for more than 100,000 human immunodeficiency virus (HIV)-related deaths per year. We tested two treatment strategies that could be more sustainable in Africa than the standard of 2 weeks of amphotericin B plus flucytosine and more effective than the widely used fluconazole monotherapy. METHODS We randomly assigned HIV-infected adults with cryptococc...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005
Thomas F Patterson Helen W Boucher Raoul Herbrecht David W Denning Olivier Lortholary Patricia Ribaud Robert H Rubin John R Wingard Ben DePauw Haran T Schlamm Peter Troke John E Bennett

BACKGROUND In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome o...

Journal: :Mycoses 1989
A N Bulo S F Bradley C A Kauffman

Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species. Synergistic inhibition of growth occurred only once with amphotericin B and cilofungin and only 2 times with flucytosine and cilofungin. Synergistic killing occurred in 5 strains with the amphotericin B-cilofungin combination and in...

Journal: :Antimicrobial agents and chemotherapy 1994
M P Haynes H R Buckley M L Higgins R A Pieringer

The alkyl glycerol ether rac-1-O-dodecylglycerol inhibited the growth of members of two genera of yeasts, Candida and Cryptococcus, and was strongly synergistic with amphotericin B. At one-half its MIC, dodecylglycerol decreased the MIC of amphotericin B by as much as 80-fold. This high degree of synergism between dodecylglycerol and amphotericin B was demonstrated against a number of species o...

Journal: :The Journal of antimicrobial chemotherapy 2008
Marçal Mariné Raquel Espada Juan Torrado F Javier Pastor Josep Guarro

OBJECTIVES Amphotericin B poly-aggregates are a new formulation of amphotericin B, which can be obtained cheaply. In this study, we tested the efficacy of this new formulation for treating a disseminated infection by Candida glabrata in a murine model. METHODS Mice were rendered neutropenic by intraperitoneal cyclophosphamide and intravenous 5-fluorouracil administration and infected intraven...

Journal: :Organic & biomolecular chemistry 2010
Barry Murphy Katie Anderson Charles Borissow Patrick Caffrey Gerald Griffith Jessica Hearn Odubunmi Ibrahim Naseem Khan Natalie Lamburn Michael Lee Katherine Pugh Bernard Rawlings

Amphotericin B is a powerful but toxic drug used against fungal infections and leishmaniases. These diseases would be treated more effectively if non-toxic amphotericin derivatives could be produced on a large scale at low cost. Genetic manipulation of the amphotericin B producer, Streptomyces nodosus, has previously led to the detection and partial characterisation of 8-deoxyamphotericin B, 16...

Journal: :The Journal of antimicrobial chemotherapy 2008
R Espada S Valdespina M A Dea G Molero M P Ballesteros F Bolás J J Torrado

OBJECTIVES The purpose of this investigation is the study of toxicity, in vivo distribution and therapeutic activity against candidiasis of poly-aggregated amphotericin B, in two different formulations: not microencapsulated (P-AMB) or incorporated in albumin microspheres (MP-AMB). METHODS The therapeutic efficacy and toxicity of amphotericin B formulations was studied in an immunocompetent m...

Journal: :Brazilian journal of biology = Revista brasleira de biologia 2016
V M Oliveira E Carraro M E Auler N M Khalil

Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting as cryptococcosis the immunocompromised patients. However, severe side effects have limited the utility of this drug. The aim of this study was to evaluate the antifungal effect of the combination of amphotericin B with quercetin or rutin and as a protective of citotoxic effect. Th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید